Virus DNX2401 and Temozolomide in Recurrent Glioblastoma

Inclusion criteria: * Patients willing and able to give informed consent and willing to comply with all the protocol procedures. * Patient must be, in the investigator opinion, able to comply with all the protocol procedures. * Age 18-75 years. * Negative pregnant test in case of fertile women. * Patient diagnosed GBM in first recurrence after radiotherapy and TMZ. Must have completed at least radiotherapy and one TMZ cycle afterwards. * Intraoperative histological verification of recurrence is needed to confirm inclusion. * Karnofsky Performance Status ≥ 70 before inclusion * Lesion considered by the investigator to be resectable or accessible for stereotactic biopsy. Lesion location will allow injection without entrance of virus in the ventricular system. * Last TMZ cycle must have been finished at least 4 weeks before entry in the study. * Must have adequate renal, bone marrow and liver function. Exclusion criteria: * Severe infections or intercurrent medical conditions including, but not limited to, severe renal, hepatic, heart or bone marrow failure, that, on investigator´s criteria, do not allow the inclusion. * Participation on another clinical trial in the previous 30 days. * Previous hypersensitivity to temozolomide or any associated components. Previous serious toxicity to temozolomide. * Subjects with immunodeficiency, autoimmune conditions or active hepatitis. * Any medical or psychological condition that might interfere with the subject's ability to participate or give informed consent. * Tumor with multiple locations, unless all the lesions are considered resectable, or all the lesions except one can be resected, and the last one can be injected; diffuse subependymal spreading or location that would need injection through ventricle. * Current diagnosis of other cancer except in situ cervical cancer, basal or squamous cell carcinoma of the skin. Patients with a history of another cancer remain eligible if they are cancer free for at least three years. * Pregnant or breast-feeding females will be excluded, due to the risk for the fetal development of a recombinant virus containing genes related to cellular growth and differentiation. * Severe bone marrow hypoplasia. * Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) \> 3 times over normal laboratory level.